The purpose of study is to evaluate efficacy, safety, and tolerability of Brexpiprazole (Rexulti) in the treatment of Bipolar I Disorder. The study consists of an inpatient stay lasting 3-4 weeks, and a follow up visit. Compensation for all participants is provided.
Criteria:
· Be a male or female aged 18-65 years old
· Have a diagnosis of Bipolar disorder and be currently experiencing more symptoms
· Be willing to discontinue all prohibited medications to meet protocol-required washouts prior to and during the trial period
· Have no history of any other diagnosis including, but not limited to, Schizophrenia, Major Depressive Disorder, ADHD, Dementia, and other cognitive or personality disorders
· Be in good physical health
· No history of seizure disorders, strokes, or tumor of the CNS
· No suicide attempt within the past 2 years
· Patients only responsive to Clozapine or unresponsive to Clozapine are excluded